

TABLE OF CONTENTS

September 29, 2008

No. 2108

BUSINESS

- 1 Drugs Will Continue to Be a Core Business of New Meiji Company
- 2 NanoCarrier Ties Up with Taiwan Company for Nanoplatin
 - Joint Research to Be Terminated with Kirin
- 2 Erbitux Launched by Merck Serono and Bristol-Myers
- 3 Astellas Ties Up with Maxygen to Develop Drugs for Autoimmune Diseases, Transplant Rejection
- 3 Quintiles to Provide Lab Data Directly Comparable with Those from Other Countries
 - Quintiles Expands Its Business Base in Asia-Pacific Region
- 4 Pure Pharma Business Model Approaching the End: Mr K. Masuzoe
- 5 DTP Focused on at 2008 IFPW General Membership Meeting
 - Drug Distribution Business Is Difficult to Enter from Abroad: Mr Kumakura
 - Standardization Essential for Supply Chain Integrity: Mr Iwasaki
 - Mr Matsutani Elected Vice President
- 6 Will Distribution Practices Be Improved?: Part 3
- 8 **BUSINESS NEWS IN BRIEF**
 - Banyu to Introduce New Marketing System by Type of Disease
 - Asmanex Twisthaler Launched in the US: Schering-Plough
 - Takeda Sues Taiyo for Contract Manufacturing of Defective Products
 - Toho to Make Dispensing Pharmacy Chain Ethos Its Wholly Owned Subsidiary
- 8 Kyowa Medex Launches New Reagent to Determine HDL-C

REGULATORY

- 10 Bristol-Myers Applies for Abatacept
- 10 Draft GL Announced for Approval of Biosimilars
- 11 PhRMA to Present Comments on Draft GL for Biosimilars Announced by *Koroshō*
- 11 *Koroshō* to Actively Hire Ex-Employees of Pharma Companies
- 12 **REGULATORY NEWS IN BRIEF**
 - Roche Receives Complete Response Letter for Actemra from the FDA
 - GSK1557484A, Sodium Phenylbutyrate Designated as Orphan Drugs
 - People Need Considerate Welfare Services: Mr Ishii
- 13 **TOPICS**
 - Number of Centenarians Up to 36,276

R&D

- 13 Pfizer to Start Clinical Trial for Fibromyalgia

13 R&D NEWS IN BRIEF

- Blopress Reduces Incidence of Diabetic Retinopathy: Takeda
- Vildagliptin Better Tolerated than TZDs: Novartis
- Aliskiren Reduces Blood Pressure in Obese Patients: Novartis
- Multaq Reduces Risk of Stroke by 34%: sanofi-aventis
- Liraglutide Improves Control of Blood Glucose
- Iressa May Be Useful in First-Line Therapy: New Data
- YPSL Improves Graft Function in High IRI-Risk Patients: Y's Therapeutics

17 TOPICS

- Prof. Yamanaka's iPS Cell Preparation Method Patented in Japan

15 NEW PRODUCT

- Julina Launched as Japan's First Oral Estradiol Product

COMMENTARY

16 Maurer's Healthcare Insight (99)

- All the News Unfit to Print: P. Reed Maurer

GENERICS

- 18 Mylan to Increase Number of MRs to 300, Open 4 More Offices
 - Efficacy, Safety of Merckmezin Confirmed in PMS: Mylan
- 18 More Prescriptions than Expected Prohibit Use of Generics: Mr Urushibata

SELF-MEDICATION

- 19 Draft Ordinance Published in Preparation for Full Enforcement of Amended PAL
 - JPA, JODA to Present Objections
 - JACDS Opposed to Both JPA and JODA

MEDICAL FACILITIES & NURSING CARE

- 20 Avastin Effective in Patients with or without K-ras Gene Mutation
- 20 Many Physicians Lack Accurate Knowledge about Medicinal Narcotics
- 21 Long-term Hospitalization for Schizophrenia Causes Problems in IADL
- 21 Measles Vaccination Rates Remain Under 40% in Teenagers: *Koroshō* Survey
- 22 Number of Lifestyle Disease-Free Persons Increases for First Time
- 22 Blood Donations Falling Sharply among Young People
- 23 Gardasil Reduces Patients' Burden: Merck
- 23 75% of People Dissatisfied with Current Social Security System